Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.

Neurobiology of disease - 1 Dec 2016

Runeberg-Roos Pia, Piccinini Elisa, Penttinen Anna-Maija, Mätlik Kert, Heikkinen Hanna, Kuure Satu, Bespalov Maxim M, Peränen Johan, Garea-Rodríguez Enrique, Fuchs Eberhard, Airavaara Mikko, Kalkkinen Nisse, Penn Richard, Saarma Mart

Abstract excerpt

In Parkinson's disease midbrain dopaminergic neurons degenerate and die. Oral medications and deep brain stimulation can relieve the initial symptoms, but the disease continues to progress. Growth factors that might support the survival, enhance the activity, or even regenerate degenerating dopamine neurons have been tried with mixed results in patients. As growth factors do not pass the blood-brain barrier, they...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amphetamine
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macaca fascicularis

Share to Oxidopamine

Share to Proto-Oncogene Proteins c-ret

Share to Rats, Wistar

Share to Stereotyped Behavior

Share to Tyrosine 3-Monooxygenase

Source

Identifiers

PMID: 27425888
DOI: 10.1016/j.nbd.2016.07.008

Genes

NRTN
GDNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.PMID 27425888Read ↗

Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.Semantic proximity Read ↗

Construction and preliminary characterization of human recombinant proNGF-A variant.Semantic proximity Read ↗

Gene therapy for Parkinson’s disease: contemporary practice and emerging conceptsSemantic proximity Read ↗

Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic Applications.Semantic proximity Read ↗

Striatal GDNF System Elicits Chemoattraction to RET Positive Dopamine Axons Seven Times Longer in Distance than the Abundant Medium Spiny Neurons and Covers Approximately One Twelfth of the Striatal Neuronal VolumeSemantic proximity Read ↗

Production of highly pure human glycosylated GDNF in a mammalian cell line.Semantic proximity Read ↗

[Nerve growth factors in future therapies. Protein mutation broadens the range of therapeutic possibilities].Semantic proximity Read ↗

Rational design, solution conformation and identification of functional residues of the soluble and structured Nogo-54, which mimics Nogo-66 in inhibiting the CNS neurite outgrowth.Semantic proximity Read ↗

Structural determinants of heparan sulphate modulation of GDNF signalling.Semantic proximity Read ↗

Development of a non invasive NGF-based therapy for Alzheimer's disease.Semantic proximity Read ↗

Construction of a mutated pro-nerve growth factor resistant to degradation and suitable for biophysical and cellular utilization.Semantic proximity Read ↗

Successful long-term bilateral subthalamic nucleus deep brain stimulation in VPS35 Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.